scanance.
Sign inGet Premium
NO

Novanta Inc.

NOVTTechnologyNASDAQ

Scientific & Technical Instruments

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$980.6M
+3.3% YoY
Net Income
$53.8M
-16.0% YoY
EBITDA
$178.6M
-0.7% YoY
Free Cash Flow
$87.3M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Novanta Inc.

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United. Valued at $5.67B, NOVT is a mid-cap name in its sector. The company operates Automation Enabling Technologies and Medical Solutions segments.

Key stats
Market Cap$5.67B
P/E (TTM)114.63
Fwd P/E38.45
EPS$1.39
Beta1.62
52W Change+30.7%
ROE5.2%
Analysis

With $388.8M in cash and $291.3M in debt, NOVT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $87.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 5.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $706.8M (2021) to $980.6M (2025), reflecting a 39% increase over the period.

A beta of 1.62 means NOVT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. At over 50x earnings, NOVT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing NOVT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms